Why didn’t the TGA consult with Australian researchers and clinicians with experience in psilocybin-assisted psychotherapy for treatment-resistant major depressive disorder?
Susan L. Rossell, Sally Meikle, M.l. Williams, David Castle
Australian & New Zealand Journal of Psychiatry May 3, 2023 DOI: 10.1177/00048674231172691 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Peer reviewed |
|---|---|
| Topics | Psilocybin Depression Psychedelic-assisted therapy |
| Keywords | Psychotherapist Hallucinogen |
| Citations | 14 |
Abstract
No description available
Citations in the library
Cited by 11
- Australia to prescribe MDMA and psilocybin for PTSD and depression in world first Nature July 13, 2023
- History, Hype, and Responsible Psychedelic Medicine: A Qualitative Study of Psychedelic Researchers. Journal of Bioethical Inquiry October 4, 2024
- Attitudes toward psychedelics and psychedelic-assisted psychotherapy among Australian mental healthcare providers Australian & New Zealand Journal of Psychiatry July 15, 2025
- Use of psychedelic treatments in psychiatric clinical practice: an EPA policy paper European Psychiatry 2025
- Lost in translation? Qualitative interviews with Australian psychedelic-assisted therapy trial clinicians. Psychology and Psychotherapy Theory Research and Practice September 16, 2024
and 6 more in the library
Cites 3
- Medicinal psychedelics for mental health and addiction: Advancing research of an emerging paradigm Australian & New Zealand Journal of Psychiatry March 21, 2021
- Translating Psychedelic Therapies From Clinical Trials to Community Clinics: Building Bridges and Addressing Potential Challenges Ahead Frontiers in Psychiatry November 4, 2021
- Psilocybin-assisted therapy for depression: How do we advance the field? Australian & New Zealand Journal of Psychiatry November 22, 2019